🔗 Share this article

Given that America undertakes sweeping adjustments to its immunization recommendations, one figure has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots throughout the global health crisis and has concentrated on alleged deaths after COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Program

Public health authorities planned to announce radical revisions to the childhood vaccine schedule recently, synchronizing the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US out of step with much of the international standard with no evidence for public health gain. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to speak at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad solidify control at the agency – and it points to a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US in order to be more similar to Denmark's approach, a society with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date statements, she has kept her attention on immunizations – traditionally the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Expertise

The appointee has no apparent background in medication creation, oversight or management, which has been typical for former heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Former heads of CBER would “grasp laws and regulations and the science of drug development”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who ran the center have had.”

This division has an enormous range of responsibilities at the FDA, she emphasized.

“Many people just pays attention on the novel medication approvals, but the generic drug division clears a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and all of those have to be supervised,” Woodcock noted. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a major management component to the role, which supervises in excess of 5,000 employees. “It is a massive leadership role, if you perform it correctly,” Woodcock concluded.

Response and Disputed Policies

In response to questions about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among FDA leaders on immunizations, a spokesperson responded that the “concerns rely on flawed presumptions”.

“Her resume aligns with the functions of her position,” the representative explained, pointing to the period Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a contentious expedited drug-approval program that apparently worried her predecessors. “By what process are these therapies being picked for this voucher program? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of most medications, aside from immunizations.”

Established Track Record on Vaccines

Concerning immunizations, Høeg has a more documented, if troubling, past, Howard said. She released a research paper using unverified public submissions to estimate the incidence of heart inflammation after Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new government included changing rules for recently developed shots and halting “non-essential” immunizations, she stated following the vote on a audio program. At the agency, Dr. Høeg has reportedly suggested preventing adolescent males from obtaining Covid vaccines.

“She’s an thorough ideologue who commences with her conclusions and tailors the evidence to fit the data in a very misleading, fraudulent fashion,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|